Quoin reports positive QRX003 data in Netherton Syndrome: IGA improves from severe to mild after 6 weeks

Quoin Pharmaceuticals, Ltd.

IGA score improved from 'severe' at baseline to 'mild' after six weeks of twice-daily QRX003 dosing.
After 12 days of dosing, IGA was 'mild-moderate'; full 6-week data confirms continued improvement.
Subject transitioned from 20% BSA treatment to whole-body application based on positive results.
No adverse events or safety concerns reported for this subject, consistent with prior studies.
Data from ongoing 12-week Investigator Pediatric Study supports QRX003's potential in Netherton Syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.